Effects of sacubitril/valsartan combined with dapagliflozin on cardiac and renal function in elderly patients with chronic heart failure
Objective To observe the clinical therapeutic effects of sacubitril/valsartan combined with dapagliflozin on elderly patients with chronic heart failure.Methods A total of 271 elderly patients with chronic heart failure treated in Depart-ment of Cardiology of Huadong Hospital Affiliated to Fudan University from July 2018 to October 2022 were retrospectively se-lected.Among them,there were 89 cases in treatment group 1 treated with valsartan alone,90 ones in treatment group 2 treated with sacubitril/valsartan,and 92 ones in treatment group 3 treated with sacubitril valsartan combined with dapagliflozin.All three groups were treated continuously for 12(10-13.5)months.The levels of serum creatinine,uric acid,left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF)and brain natriuretic peptide(BNP)were compared among the three groups before and after treatment.Results After 12(10-13.5)months of treatment,the clinical effective rate of the treatment group3 was95.7%,which was significantly higher than that of the treatment group 1(80.9%)(P＜0.05).Compared with before treatment,the cardiac function indexes in all groups were significantly improved,and renal func-tion indexes in the treatment group3 were significantly improved(P＜0.05).In terms of LVEF improvement,the treatment group 3 and treatment group 2 were superior to the treatment group 1.In terms of LVEDD,serum creatinine,and uric acid im-provement,the treatment group 3 was superior to the treatment group 2 and treatment group 1.In terms of BNP improvement,the treatment group 3 was superior to the treatment group 1.All the above results were statistically significant(P＜0.05).Conclusion All three treatment regimens can improve the cardiac and renal function indicators in elderly patients with chronic heart failure.However,compared to the use of valsartan alone or sacubactril/valsartan,the combination of sacubitril/valsartan with dapagliflozin in the treatment of elderly patients with chronic heart failure has the greatest cardiac and renal benefits.
国家科技期刊平台
NSTL
万方数据
